Log in  First Connection?

SchizophreniaArchives

Suicide risk, psychopathology and cognitive impairments in schizophrenia with insomnia: a large-scale cross-sectional study
Schizophrenia
 5 min.

 Published on 07/10/2025 |  Original article (Full-text)  | Lu Chenghao et al. | BMC Psychiatry 2025; 25(1): 920

Schizophrenia is a serious and common chronic mental disorder associated with higher mortality rate compared to the general population [1]. Suicide is notably common among patients with schizophrenia globally and is a leading cause of death among these patients [2]. In China, the lifetime prevalence...

Feasibility of a digital therapeutic for experiential negative symptoms of schizophrenia: results from an exploratory study
Schizophrenia
 7 min.

 Published on 30/09/2025 |  Original article (Full-text)  | Goenjian Haig et al. | Schizophrenia 2025; 11(1): 120

Schizophrenia is a complex and disabling psychiatric disorder that affects approximately 0.45% of adults worldwide1 and 0.25–64% of adults in the US2, 3–4, imposing a substantial health, social, and economic burden5,6. Furthermore, schizophrenia disproportionately impacts marginalized communities,...

The associations between insomnia symptoms and clinical features, lipid metabolism parameters, as well as inflammatory cytokines in patients with chronic schizophrenia
Schizophrenia
 6 min.

 Published on 23/09/2025 |  Original article (Full-text)  | Liu Lewei et al. | BMC Psychiatry 2025; 25(1): 830

Schizophrenia is a prevalent severe psychiatric disorder marked by cognitive dysfunction, hallucinations, delusions, and disorganized behaviors [1]. According to the latest epidemiological survey data, the lifetime prevalence of schizophrenia in China was 0.7% [2]. Compared with other mental disorders,...

Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia
Schizophrenia
 6 min.

 Published on 16/09/2025 |  Original article (Full-text)  | Lauriello John et al. | Advances in Therapy 2025; 42(9): 4350-66

Clinical practice guidelines for the treatment of schizophrenia recommend continuous treatment with antipsychotic medication to reduce acute symptoms, prevent their recurrence, and maximize quality of life [1]. However, nonadherence to oral antipsychotic medication is common among some patients with...